Drug intelligence / Profile preview

Newnorm

Development stage: Phase 3
Lead developer: Octapharma
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Newnorm is a 20% human normal immunoglobulin formulated for subcutaneous (SC) infusion. Developed by Octapharma, it is currently in Phase 3 clinical trials for the treatment of primary immunodeficiency diseases. This biologic drug aims to provide passive immunity by replacing deficient antibodies and to modulate the immune system, offering a more convenient administration method compared to traditional intravenous immunoglobulin therapies.

Brand names: Newnorm

Targets

Complement (Complement system)

Beyond the preview

Go deeper on Newnorm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newnorm.

Explore the full profile